Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Caridad Pontes*, Corinne Zara, Josep Torrent-Farnell, Merce Obach, Cristina Nadal, Patricia Vella-Bonanno, Michael Ermisch, Steven Simoens, Renata Curi Hauegen, Jolanta Gulbinovic, Angela Timoney, Antony P. Martin, Tanja Mueller, Anna Nachtnebel, Stephen Campbell, Gisbert Selke, Tomasz Bochenek, Celia C. Rothe, Ileana Mardare, Marion BennieJurij Fürst, Rickard E. Malmstrom, Brian Godman

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Fingerprint Dive into the research topics of 'Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab'. Together they form a unique fingerprint.

Business & Economics

Medicine & Life Sciences